Intersect ENT, Inc. - Common Stock (NQ:XENT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 12, 2022 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	28.24 (1,000)
Ask (Size)	29.25 (200)
Prev. Close	28.24
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	33,314,586
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

January 25, 2022

From Intersect ENT, Inc.

Via Business Wire

Intersect ENT Reports Third Quarter 2021 Financial Results

November 02, 2021

From Intersect ENT, Inc.

Via Business Wire

Performance

More News

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

October 28, 2021

From Intersect ENT®, Inc.

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, LMRK, XENT, JAX; Shareholders are Encouraged to Contact the Firm

September 13, 2021

From Halper Sadeh LLP

Via AccessWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, GTS, XONE, XENT; Shareholders are Encouraged to Contact the Firm

September 04, 2021

From Halper Sadeh LLP

Via AccessWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CSOD, XENT, FFWM, RIVE; Shareholders are Encouraged to Contact the Firm

August 19, 2021

From Halper Sadeh LLP

Via AccessWire

INVESTIGATION: Halper Sadeh LLP Investigates NLOK, XENT, NWHM; Shareholders are Encouraged to Contact the Firm

August 12, 2021

From Halper Sadeh LLP

Via AccessWire

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021 ↗

August 12, 2021

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 ↗

August 09, 2021

Via Benzinga

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗

August 11, 2021

Via Benzinga

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗

August 10, 2021

Via Benzinga

INTERSECT ENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intersect ENT - XENT

August 06, 2021

From Kahn Swick & Foti, LLC

Via Business Wire

Why Intersect ENT Shot 12% Higher on Friday ↗

August 06, 2021

Via The Motley Fool

Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT

August 06, 2021

From Halper Sadeh LLP

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 06, 2021

Via Benzinga

Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share ↗

August 06, 2021

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 06, 2021

Via Benzinga

Intersect ENT: Q2 Earnings Insights ↗

August 06, 2021

Via Benzinga

Intersect ENT Reports Second Quarter 2021 Financial Results

August 06, 2021

From Intersect ENT, Inc.

Via Business Wire

U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

July 26, 2021

From Intersect ENT

Via Business Wire

Earnings Scheduled For August 6, 2021 ↗

August 06, 2021

Via Benzinga

Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding ↗

July 23, 2021

Via Benzinga

Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

July 23, 2021

From Intersect ENT, Inc.

Via Business Wire

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan

July 22, 2021

From Intersect ENT, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021 ↗

June 24, 2021

Via Benzinga

Frequently Asked Questions

Is Intersect ENT, Inc. - Common Stock publicly traded?

Yes, Intersect ENT, Inc. - Common Stock is publicly traded.

What exchange does Intersect ENT, Inc. - Common Stock trade on?

Intersect ENT, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Intersect ENT, Inc. - Common Stock?

The ticker symbol for Intersect ENT, Inc. - Common Stock is XENT on the Nasdaq Stock Market